Melphalan intravenous - Spectrum Pharmaceuticals

Drug Profile

Melphalan intravenous - Spectrum Pharmaceuticals

Alternative Names: Captisol-Enabled® melphalan; CE melphalan; CE-Melphalan HCl; EVOMELA; LGD-353; Melphalan intravenous - CyDex; sulfobutylether β-cyclodextrin-enabled melphalan

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer CASI Pharmaceuticals; Spectrum Pharmaceuticals
  • Class Amino acids; Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 05 Dec 2016 Preregistration for Multiple myeloma in China (IV)
  • 05 May 2016 Launched for Multiple myeloma in USA (IV) before May 2016
  • 20 Apr 2016 Sulfobutylether β-cyclodextrin-enabled melphalan receives Orphan Drug status as a high-dose conditioning treatment prior to haematopoietic progenitor (stem) cell transplantation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top